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Figure 1. Patient’s profile shows obesity and diffuse goiter in her neck
Figure 2. Thyroid ultrasound shows diffuse goiter
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Association between diabetes and thyroid 
dysfunction has been recognized since long 
time ago.1 Prevalence of thyroid dysfunction is 
higher in type 2 diabetes population compared 
to normal population.1-3 A meta-analysis by 
Han C4 obtained the pool adjusted prevalence 
of subclinical hypothyroidism around 10.2% 
among type 2 diabetes patients. This meta-
analysis use 36 studies around the world with 
the range prevalence from 4.69-18.86%.4 This 
phenomenon is very interesting in endocrinology 
field since several risk factors may contribute to 
hypothyroidism in type 2 diabetes patients, such 
as advanced age, female gender, poor glycemic 
control, metabolic syndrome, family history of 
thyroid diseases, and the use of metformin.5-10
As thyroid hormone has an important roles 
in body metabolism, hypothyroidism is usually 
accompanied by several metabolic parameters 
which can be improved as the patient has 
thyroxin substitution therapy.11 These metabolic 
conditions include dyslipidemia, poor glycemic 
control, and obesity. Therefore, assessment 
of thyroid function is an integral part of 
comprehensive management of type 2 diabetes 
mellitus patients, especially with obesity, 
dyslipidemia, and metabolic syndrome. It is also 
recommended by American Thyroid Association 
(ATA),12 European Thyroid Association (ETA),13 
and British Thyroid Foundation.14
This is a case of 51 year-old woman with 
uncontrolled type 2 diabetes mellitus which was 
diagnosed 1.5 year earlier, obesity with body 
mass index 32.2 kg/m2, waist circumference of 
113 cm, diffuse goiter with neck circumference 
40 cm, and hypertension with blood pressure 
>140/90 mmHg. Since 6 months ago, she 
often seemed like having less concentration 
or daydreaming, chronic fatigue, depression, 
and low food intake. Her body weight had 
been increasing over time. Her hypothyroidism 
clinical scoring Billewicz and Zulewski criterias 
were 17 and 8 respectively, showing that she 
tended to experience hypothyroidism. From 
laboratory examination, fasting blood glucose 
was 216 mg/dL and 2-hour postprandial blood 
glucose was 320 mg/dL with level of HbA1c was 
9.9%, triglyceride level was 486 mg/dL, HDL 
cholesterol 46 mg/dL, LDL cholesterol 157 mg/
dL, and total cholesterol was 269 mg/dL. Thyroid 
ultrasound showed a diffuse goiter in both lobes 
of her thyroid gland.
Thyroid function examination was performed 
and the result was subclinical hypothyroidism 
with TSHs 74.83 mIU/L (normal 0.27-4.2 mIU/L) 
and free-T4 1.02 mg/L (normal 0.93-1.70 mg/L). 
She was diagnosed as having uncontrolled type 
2 diabetes mellitus with metabolic syndrome, 
obesity, and severe hypertriglyceridemia, and 
subclinical hypothyroidism based on laboratory 
examination. Although hypothyroidism is 
actually at the clinical stage and based on clinical 
presentation. She was treated with analogue 
rapid-acting insulin (aspart) 12 unit three-times 
daily and analogue long-acting insulin (glargine) 
14 unit once daily, which was the same dose of 
insulin she took before. According to European 
Thyroid Association (ETA) Guideline for 
subclinical hypothyroidism,13 she had been given 
levothyroxin 100 µg once daily.
After one month therapy of thyroxin, 
symptoms were getting better such as more active 
physically, less symptoms of depression, reduced 
weight with the same insulin dose. The TSHs level 
decreased to 29.15 mIU/L. After three months of 
thyroxin therapy, hypothyroidism symptoms are 
reduced with Billewicz score and Zulewski score 
7 and 5 respectively. Body mass index reduced 
to 31.5 kg/m2, waist circumference 106 cm, neck 
circumference 37 cm, and normal blood pressure. 
HbA1c level decreased to 9% with same insulin 
dose, triglyceride 223 mg/dL, HDL cholesterol 
54 mg/dL, LDL cholesterol 145 mg/dL, and total 
cholesterol 255 mg/dL. Clinical and laboratory 
metabolic parameters were improved, although 
patient had not regular exercise and insulin dose 
were remain steady. Her TSHs level decreased 
to 13.19 mIU/L after three months of thyroxine 
therapy.
After six months therapy of levothyroxin, 
the clinical presentation resolved; no depression 
symptoms, more active physically, and decreased 
body mass index. Her TSHs level is 5.81 mIU/L 
with free-T4 1.55 mg/L, HbA1c 7.8% (fasting 
blood glucose 162 mg/dL and 2-hour post-
prandial blood glucose 155 mg/dL with the 
same insulin dose, triglyceride 176 mg/dL, HDL 
cholesterol 48 mg/dL, LDL cholesterol 106 mg/
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dL, and total cholesterol 173 mg/dL.
Hypothyroidism in type 2 diabetes mellitus 
patient can worsen morbidities such as obesity 
and dyslipidemia, which contribute to more 
complications, mortality risk, and decrease 
quality of life.15 Routine screening of thyroid 
function in type 2 diabetes mellitus patients still 
controversial nowadays. Not all endocrine and 
diabetes societies mention thyroid function in 
the list of diabetes panel examination like lipid 
profiles, kidney function, microalbuminuria, and 
electrocardiography. In the other hand, several 
thyroid societies all over the world insert type 2 
diabetes mellitus as a condition which thyroid 
function test suggested to be examined.12-14 
Therefore, screening of thyroid function in 
diabetes patient must be right on target. If the 
patient’s clinical presentation has a tendency 
to develop hypothyroidism, such as obesity, 
metabolic syndrome, poor glycemic control, 
goiter, low activity, slow movement, bradycardia, 
chronic fatigue, examination of thyroid function 
is mandatory.
The patient in this medical illustration is a 
good example of thyroxin treatment which can 
improve several metabolic parameters. Gluvic 
Z et al11 and Kumar A et al16 reported significant 
metabolic effects of thyroxin replacement 
therapy in hypothyroid patients will improve 
metabolic syndrome and atherosclerosis. This 
contributes to reduced cardiovascular risk in 
diabetes population, as they are already have 
higher risk of cardiovascular events.11 In our 
patient, as the TSH level decreased gradually, the 
HbA1c, lipid profiles, fasting blood glucose and 
2-hour post-prandial blood glucose, body mass 
index, waist circumference, neck circumference 
had also been reduced. More studies are needed 
to investigate the hard endpoint such as major 
cardiovascular event and mortality.
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